OBIGEN Pharma&rsquo;s OBI-858 is approved by MINISTRY OF LAW AND HUMAN RIGHTS OF REPUBLIC OF INDONESIA,&nbsp;DIRECTORATE GENERAL OF INTELLECTUAL PROPERTY on 27<span style="box-sizing: border-box; font-size: inherit; line-height: 0; position: relative; vertical-align: baseline; top: -0.1em; margin: 0px; padding: 0px; border: 0px; color: #3a3a3a; font-family: Calibri, sans-serif; background-color: #ffffff;">th May 2024. No.&nbsp;HKI-3-KI.05.01.08-DP-P00202109681 with the title of invention as&nbsp;&ldquo;CLOSTRIDIUM BOTULINUM TOXIN TYPE A COMPOSITION, FORMULATION AND USE THEREOF&rdquo;, authorization notice as the below.
<img src="/uploads/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80_%E9%87%8D%E5%A4%A7%E5%85%AC%E5%91%8A/%E5%8D%B0%E5%B0%BC_P00202109681%20NOA.jpg" alt="印尼_P00202109681 NOA.jpg" width="2481" height="3509" />

OBI-858 Approved by Indonesia DIRECTORATE GENERAL OF INTELLECTUAL PROPERTY, No. HKI-3-KI.05.01.08-DP-P00202109681